EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

B-cell activation markers and cancer risk in people with HIV: An integrative case-control and Mendelian randomization analysis

Ricardo Cortez Cardoso Penha, Ramya Ramaswami, Jacqueline Nordwall, Andrew Phillips, Marie Helleberg, Anuradha Ganesan, Jennifer Hoy, Sophie Grabar, Duncan Gilbert, Angela Crook, Ellen Kitchell, Jakob J Malin und 5 weitere

JNCI Cancer Spectrum · 06.11.2026

DOI: 10.1093/jncics/pkag119 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 06.11.2026. Verfasst von Ricardo Cortez Cardoso Penha und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Health, Immunity and Infections (CHIP) and INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) Co….

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early and continuous antiretroviral therapy (ART) reduces cancer risk in people with HIV (PWH), yet residual risk potentially driven by persistent B-cell activation remains. We used observational and genetic triangulation to evaluate whether baseline B-cell biomarkers are associated with subsequent cancer risk. We conducted: (i) a nested case-control study within the INSIGHT trials (158 cases and 313 matched controls) assessing B-cell biomarkers (sCD23, sCD27, sCD30, CXCL13) in PWH; and (ii) two-sample Mendelian randomization (MR) to evaluate likely causal relationships between these proteins and 23 cancer types using general-population genome-wide association studies. Median time from study entry to cancer diagnosis was 2.9 years. In PWH, CXCL13 was associated with overall cancer risk (highest tertile vs. lowest tertile OR 2.36, 95% CI 1.24–4.5), driven by infection-related cancers (N = 82; OR 4.81, 1.76–13.1) and lymphoma (N = 36; OR 9.92, 1.58–62.2). The CXCL13 association remained robust among virally suppressed participants (P = 0.018). sCD30 was also associated with infection-related cancers (OR 2.77, 1.09–7.03). sCD23 showed a linear association with infection-related cancer (OR per SD 1.42, 1.01-2.00), though tertile-based analyses were non-significant. In the general population, MR meta-analyses showed null associations for these biomarkers across 23 cancer types (P > 0.05). Our study links B-cell markers with cancer risk in PWH, identifying CXCL13 as a marker of infection-related cancer risk despite effective ART, highlighting a "residual inflammatory gap" for modern risk stratification. The lack of causal MR signals suggests these proteins are markers of HIV-associated immune activation rather than universal etiological factors for cancer.

Autor:innen und Institutionen

  • Centre of Excellence for Health, Immunity and Infections (CHIP) and INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) Copenhagen International Coordinating Center, Copenhagen, Denmark.
  • HIV and AIDS Malignancy Branch, Center for Cancer Research, NCI, Bethesda, MD, USA.
  • Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
  • Institute of Global Health, University College London, London, UK.
  • Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, & Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Zitieren

APA

Penha, R. C. C., Ramaswami, R., Nordwall, J., Phillips, A., Helleberg, M., Ganesan, A., Hoy, J., Grabar, S., Gilbert, D., Crook, A., Kitchell, E., Malin, J. J., Achhra, A., Kumarasamy, N., Reilly, C. S., Milojevic, M., & Lundgren, J. (2026). B-cell activation markers and cancer risk in people with HIV: An integrative case-control and Mendelian randomization analysis. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkag119

Vancouver

Penha RCC, Ramaswami R, Nordwall J, Phillips A, Helleberg M, Ganesan A, et al. B-cell activation markers and cancer risk in people with HIV: An integrative case-control and Mendelian randomization analysis. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkag119

BibTeX
@article{Penha2026,
  author = {Penha, Ricardo Cortez Cardoso and Ramaswami, Ramya and Nordwall, Jacqueline and Phillips, Andrew and Helleberg, Marie and Ganesan, Anuradha and Hoy, Jennifer and Grabar, Sophie and Gilbert, Duncan and Crook, Angela and Kitchell, Ellen and Malin, Jakob J and Achhra, Amit and Kumarasamy, Nagalingeswaran and Reilly, Cavan S and Milojevic, Maja and Lundgren, Jens},
  title = {B-cell activation markers and cancer risk in people with HIV: An integrative case-control and Mendelian randomization analysis},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  doi = {10.1093/jncics/pkag119}
}
Kostenlos starten →